Pharvaris (NASDAQ:PHVS) Reaches New 12-Month High – Should You Buy?

Pharvaris N.V. (NASDAQ:PHVS)’s share price reached a new 52-week high during trading on Friday . The company traded as high as $29.89 and last traded at $29.6450, with a volume of 45241 shares trading hands. The stock had previously closed at $28.78.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Wolfe Research began coverage on Pharvaris in a research note on Thursday, April 9th. They issued an “outperform” rating and a $42.00 price target for the company. Wall Street Zen cut Pharvaris from a “sell” rating to a “strong sell” rating in a research note on Monday. Wedbush raised their price objective on Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a research note on Thursday, January 22nd. Finally, HC Wainwright restated a “buy” rating and issued a $60.00 price objective on shares of Pharvaris in a research note on Tuesday, March 3rd. Eleven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $42.73.

Pharvaris Stock Down 0.7%

The stock has a market capitalization of $1.87 billion, a PE ratio of -8.48 and a beta of -2.58. The firm has a 50 day moving average price of $27.20 and a 200-day moving average price of $25.63.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings data on Friday, April 3rd. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.15). Equities analysts expect that Pharvaris N.V. will post -2.71 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Berndt Modig sold 23,333 shares of the firm’s stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $27.74, for a total transaction of $647,257.42. Following the sale, the chief executive officer directly owned 142,084 shares of the company’s stock, valued at $3,941,410.16. This trade represents a 14.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 11.84% of the stock is currently owned by company insiders.

Institutional Trading of Pharvaris

Several hedge funds and other institutional investors have recently bought and sold shares of PHVS. Geode Capital Management LLC grew its holdings in Pharvaris by 41.1% during the second quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock worth $952,000 after acquiring an additional 15,769 shares during the period. JPMorgan Chase & Co. grew its holdings in Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after acquiring an additional 783 shares during the period. Legal & General Group Plc grew its holdings in Pharvaris by 17.2% during the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after acquiring an additional 1,695 shares during the period. Amundi grew its holdings in Pharvaris by 2,741,600.0% during the second quarter. Amundi now owns 27,417 shares of the company’s stock worth $489,000 after acquiring an additional 27,416 shares during the period. Finally, The Manufacturers Life Insurance Company grew its holdings in Pharvaris by 19.2% during the second quarter. The Manufacturers Life Insurance Company now owns 48,857 shares of the company’s stock worth $860,000 after acquiring an additional 7,879 shares during the period.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.